HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Post-Pandemic Stocks

1,557.889

+31.0702.03%

Number of Gainers:7

Number of Losers:8

Number of Flat:3

PE:- -

High:1,574.012

Open:1,526.678

Low:1,513.941

Close:1,526.819

Volume:746.51M

Turnover:8.88B

Market Cap:1.03T

Float Cap:872.46B

Loading ...

BYD Company Limited Takes Legal Action Against Great Wall Motors Executive Who Has Been Missing for Two Months

BYD Launches New Offensive in Japan

BRIEF-Ascletis Announces Results Of Subcutaneous Depot Maintenance Formulation Of Small Molecule GLP-1R Agonist ASC30 Testing

Ascletis Pharma Says Asc30 Shows 75-Day Half-Life In U.S. Phase Ib Study

Ascletis Announces Ultra-Long-Acting Subcutaneous Depot Maintenance Formulation of Small Molecule Glp-1R Agonist Asc30 Demonstrated an Observed Half-Life of 75 Days in Participants With Obesity

THOMSON REUTERS

ASCLETIS-B (01672): Small Molecule GLP-1R Agonist ASC30's Ultra-Long-Acting Subcutaneous Depot Formulation for Weight Maintenance Demonstrates 75-Day Apparent Half-Life in Obese Subjects

Ascletis Pharma Inc. Announces Phase IIa Study of ASC30 for Obesity Treatment with Promising Half-Life Results

Yiteng Pharmaceuticals, Shanghai Pudong Development Bank Hong Kong Branch, Suzhou Branch, and SPDB International Sign Strategic Cooperation Agreement

BYD Electronic (International) Stock Slides 2.0% in Hong Kong

ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs

CISI FIN Maintains "Buy" Rating on BYD ELECTRONIC (00285), Profitability Improves in 2025H1

Sihuan Pharmaceutical Receives Chinese Regulatory Nod for Human Studies of Diabetes Drug

MT Newswires Live

Hong Kong Stocks Movement | Most Internet Healthcare Stocks Rise as National Medical Products Administration Regulates Online Prescription Drug Retail, Institutions Recommend Focusing on Industry Recovery Opportunities

Hong Kong Stocks Movement | JUNSHI BIO (01877) Surges Over 9% as JS005 Achieves Positive Results in Phase III Clinical Trial for Moderate to Severe Plaque Psoriasis

BRIEF-Sihuan Pharmaceutical Says P052 Injection Approved For Ind

Morgan Stanley Initiates Buy Rating on FOSUN PHARMA (02196) with A-Share Target Price of 42 RMB and H-Share Target Price of 33 HKD

SIHUAN PHARM (00460): Subsidiary Huisheng Bio Receives IND Approval for Self-Developed GLP-1R/GCGR Dual-Target Innovative Drug P052 Injection

Sihuan Pharmaceutical - P052 Injection Independently Developed by Huisheng Biopharmaceutical Approved for Ind

THOMSON REUTERS

KINTOR PHARMA-B (09939): KT-939 Human Long-term Safety Trial Completes Full Subject Enrollment

Kintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1515/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":1557.8887,"timestamp":1757405290965,"preClose":1526.8188,"halted":0,"volume":746507675,"delay":0,"changeRate":0.020349,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":31.069824,"latestTime":"09-09 16:00:00","open":1526.6782,"high":1574.012,"low":1513.9413,"amount":8881416211,"amplitude":0.039344,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757467800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1757381400000,1757390400000],[1757394000000,1757404800000]],"pbRate":2.420622,"peRate":31.997398,"turnoverRate":0.009928,"increases":5,"decrements":10,"flats":2,"marketCap":1030672858624,"floatMarketCap":872462083456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":1574.012,"amplitude":0.039344,"preClose":1526.8188,"low":1513.9413,"pbRate":"2.420622","latestPrice":1557.8887,"volume":746507675,"delay":0,"open":1526.6782,"prevYearClose":787.97723,"prevWeekClose":1516.227,"prevMonthClose":1413.928,"prevQuarterClose":1028.719,"fiveDayClose":1473.257,"twentyDayClose":1291.398,"sixtyDayClose":1050.09,"secType":"PLATE","market":"HK","turnoverRate":0.009928,"peRate":31.997398,"marketCap":1030672858624,"floatMarketCap":872462083456,"timestamp":1757405290965,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":7,"down":8,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1193250319","title":"BYD Company Limited Takes Legal Action Against Great Wall Motors Executive Who Has Been Missing for Two Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1193250319","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193250319?lang=en_us&edition=fundamental","pubTime":"2025-09-09 22:41","pubTimestamp":1757428870,"startTime":"0","endTime":"0","summary":"Recently, BYD Company Limited has filed a lawsuit against Chang Yao, CEO of Great Wall Motors' Tank brand, on grounds of online infringement. The case has been registered at Beijing Fourth...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516422952.EUR","LU2476274720.SGD","LU0229945570.USD","LU1861214812.USD","002594","BK1594","LU0594300419.USD","LU1188198961.HKD","LU0588545730.USD","SG9999015945.SGD","LU1813983027.USD","BK1504","BK0155","LU0143863784.USD","LU2476274308.USD","LU1808992512.USD","LU0634319403.HKD","BK0014","LU0509642566.USD","LU0274383008.USD","LU1770034418.SGD","LU0463099449.HKD","LU0254981946.USD","LU1861219969.SGD","LU0348805143.USD","BK1522","LU0828238088.HKD","LU0289961442.SGD","LU0175139822.USD","LU0164872284.USD","LU2506951792.HKD","LU0143863198.USD","LU0543330566.HKD","LU0819121731.USD","LU0289739343.SGD","SG9999006514.SGD","LU0269904917.USD","LU2580892862.HKD","LU1146622755.USD","LU0214875030.USD","LU0039217434.USD","LU0823414551.USD","LU0417516738.SGD","LU1961090484.USD","LU0348735423.USD","BK0188","LU2153592121.USD","LU2097828557.USD","LU0327786744.USD","LU0819123356.HKD","LU2449936058.SGD","SG9999006597.SGD","BK1515","LU0417516902.SGD","LU0511384066.AUD","LU0531971595.HKD","LU0856984785.SGD","LU1251922891.USD","LU2097828631.EUR","LU1720050803.USD","LU0165289439.USD","LU1868838027.USD","LU0561508036.HKD","LU1868837565.USD","LU0320764599.SGD","LU0326950275.SGD","LU0823414478.USD","LU1868837722.USD","BK0183","LU1508157978.USD","LU0315178854.USD","LU0259732245.USD","LU1880383440.USD","LU0359201612.USD","BK0072","LU2360107325.USD","LU0348767384.USD","SG9999002463.SGD","LU0588546209.SGD","BK1540","LU2097828714.EUR","LU0516423174.USD","LU0865486749.SGD","BYDDY","LU0588545904.SGD","LU0633140560.USD","BK0264","81211","LU1969619763.USD","LU0605514214.HKD","HYDD.SI","LU0823426308.USD","BK0169","SG9999001226.SGD","LU0823038988.USD","BK0070","LU0348827113.USD","LU1242518931.SGD","BK1589","LU0314109678.HKD","LU0348825331.USD","IE00BD6J9T35.USD","LU2399975544.HKD","LU1064130708.USD","LU0359201885.HKD","LU0469268626.HKD","LU0531970944.HKD","LU2039709279.SGD","LU1719994722.HKD","BK1582","LU1794554557.SGD","LU0052750758.USD","LU2663582299.SGD","LU1781817850.SGD","BK1509","SG9999002828.SGD","LU2289578879.USD","LU2249611893.SGD","LU0650527681.SGD","LU0348766576.USD","LU0516422366.SGD","LU0708995583.HKD","LU0516422440.USD","LU2357125470.USD","LU0054450605.USD","SG9999014674.SGD","LU0516423091.SGD","LU0588545490.SGD","LU2328871848.SGD","BK1539","SG9999015986.USD","LU0594300179.USD","LU0307460666.USD","LU0505663152.USD","BK0196","LU0979878070.USD","LU2495084118.USD","LU0244354667.USD","SG9999015952.SGD","LU1997244956.HKD","LU0289960550.SGD","LU1580142542.USD","BK1580","LU0823426480.USD","LU0540923850.HKD","LU1997245177.USD","LU0593848301.USD","LU0683595622.HKD","LU1303224171.USD","LU2294711713.HKD","LU0359202008.SGD","LU2580892789.USD","LU0871576103.HKD","BK1119","LU0823039010.USD","LU1820825898.SGD","LU0633140727.USD","LU1242518857.USD","BK1149","LU0211977185.USD","LU2097828805.USD","LU1328277881.USD","LU2097828474.EUR","LU2778985437.USD","BK1607","BK1610","01211","LU0043850808.USD","LU1023057109.AUD","SG9999015978.USD","EVS.SI","LU0164865239.USD","LU2148510915.USD","00285","LU0572944931.SGD","LU2348774022.SGD","LU0449515922.USD","LU1997245094.SGD","LU0084288322.USD","LU1064131003.USD","LU0449509016.USD","LU1880383366.USD"],"gpt_icon":1},{"id":"1198468098","title":"BYD Launches New Offensive in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=1198468098","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198468098?lang=en_us&edition=fundamental","pubTime":"2025-09-09 21:33","pubTimestamp":1757424832,"startTime":"0","endTime":"0","summary":"At the end of last month, BYD Company Limited initiated a month-long promotional campaign in Japan with price reductions equivalent to approximately 24,200-56,700 yuan in Chinese currency, bringing...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0531970944.HKD","EVS.SI","LU0505663152.USD","LU0463099449.HKD","SG9999006514.SGD","LU1770034418.SGD","LU0543330566.HKD","LU0509642566.USD","LU2294711713.HKD","LU2506951792.HKD","BK1607","LU0348735423.USD","SG9999015978.USD","LU0315178854.USD","BK0155","LU0979878070.USD","LU1997244956.HKD","LU0823426480.USD","00285","LU1242518931.SGD","LU0634319403.HKD","LU0516423091.SGD","LU0588545730.USD","LU0043850808.USD","BK0264","LU0588545904.SGD","BK0183","LU1794554557.SGD","LU0511384066.AUD","LU2360107325.USD","LU0307460666.USD","SG9999015986.USD","BK1589","LU0516423174.USD","LU0084288322.USD","LU1969619763.USD","BK1149","LU0417516738.SGD","LU0449509016.USD","LU0594300419.USD","LU0823039010.USD","LU1146622755.USD","BK0188","BK0070","LU0289961442.SGD","BK0196","LU2097828714.EUR","LU2449936058.SGD","LU0254981946.USD","LU1188198961.HKD","LU2153592121.USD","LU0214875030.USD","LU1251922891.USD","LU1961090484.USD","LU0143863784.USD","LU0588545490.SGD","SG9999002828.SGD","LU1813983027.USD","BK1509","LU1064131003.USD","LU0289739343.SGD","LU0594300179.USD","LU1781817850.SGD","LU2097828631.EUR","LU1242518857.USD","LU0572944931.SGD","LU0274383008.USD","LU2348774022.SGD","LU0359201612.USD","LU2476274720.SGD","LU0054450605.USD","LU0359202008.SGD","LU2097828474.EUR","LU0348827113.USD","LU0856984785.SGD","01211","LU0314109678.HKD","LU1820825898.SGD","LU2289578879.USD","LU0326950275.SGD","LU1719994722.HKD","LU2495084118.USD","BK1540","LU1328277881.USD","LU0516422366.SGD","LU0819121731.USD","LU0164865239.USD","LU1861219969.SGD","BK0072","BYDDY","LU0269904917.USD","LU0683595622.HKD","LU1868837565.USD","LU0211977185.USD","LU0708995583.HKD","LU0633140727.USD","LU2148510915.USD","LU0259732245.USD","BK1582","BK1522","LU0143863198.USD","LU0828238088.HKD","LU1997245094.SGD","LU2399975544.HKD","BK1610","LU0348805143.USD","LU0516422440.USD","LU0633140560.USD","LU0593848301.USD","81211","LU2097828557.USD","LU2476274308.USD","BK0014","BK1515","LU0823426308.USD","LU0540923850.HKD","SG9999014674.SGD","LU1580142542.USD","LU0823038988.USD","SG9999001226.SGD","LU2357125470.USD","BK1539","HYDD.SI","LU2097828805.USD","LU2249611893.SGD","SG9999006597.SGD","LU1303224171.USD","LU1868837722.USD","LU0823414551.USD","LU0531971595.HKD","LU0650527681.SGD","LU2580892789.USD","LU0871576103.HKD","LU0348766576.USD","LU0449515922.USD","LU1023057109.AUD","LU2580892862.HKD","LU0052750758.USD","BK1580","LU0320764599.SGD","LU2328871848.SGD","LU0561508036.HKD","LU0819123356.HKD","LU1720050803.USD","LU0865486749.SGD","LU1868838027.USD","LU1880383440.USD","LU1508157978.USD","LU1880383366.USD","BK1594","LU0348767384.USD","LU1808992512.USD","BK1119","LU1861214812.USD","LU0327786744.USD","LU0165289439.USD","SG9999002463.SGD","LU0469268626.HKD","LU0605514214.HKD","LU2778985437.USD","LU0244354667.USD","LU0823414478.USD","002594","LU0175139822.USD","LU0039217434.USD","LU1064130708.USD","LU0348825331.USD","SG9999015952.SGD","LU0417516902.SGD","LU0289960550.SGD","BK1504","LU2039709279.SGD","LU1997245177.USD","LU0359201885.HKD","SG9999015945.SGD","LU0516422952.EUR","BK0169","LU0588546209.SGD","LU2663582299.SGD","LU0229945570.USD","LU0164872284.USD","IE00BD6J9T35.USD"],"gpt_icon":1},{"id":"2566969644","title":"BRIEF-Ascletis Announces Results Of Subcutaneous Depot Maintenance Formulation Of Small Molecule GLP-1R Agonist ASC30 Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2566969644","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566969644?lang=en_us&edition=fundamental","pubTime":"2025-09-09 18:41","pubTimestamp":1757414483,"startTime":"0","endTime":"0","summary":"BRIEF-Ascletis Announces Results Of Subcutaneous Depot Maintenance Formulation Of Small Molecule GLP-1R Agonist ASC30 TestingSept 9 (Reuters) - Ascletis Pharma Inc 1672.HK:ASCLETIS ANNOUNCES ULTRA-LON","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nTUA6LLHLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01672","BK1161","BK1574"],"gpt_icon":0},{"id":"2566966756","title":"Ascletis Pharma Says Asc30 Shows 75-Day Half-Life In U.S. Phase Ib Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2566966756","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566966756?lang=en_us&edition=fundamental","pubTime":"2025-09-09 18:37","pubTimestamp":1757414261,"startTime":"0","endTime":"0","summary":"Sept 9 (Reuters) - Ascletis Pharma Inc <1672.HK>::*ASC30 SHOWS 75-DAY HALF-LIFE IN U.S. PHASE IB STUDY*Further company coverage: 1672.HK* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 09-SEP-202510:27:29 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nRSDyGlSL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01672","BK1161","BK1574"],"gpt_icon":0},{"id":"2566374696","title":"Ascletis Announces Ultra-Long-Acting Subcutaneous Depot Maintenance Formulation of Small Molecule Glp-1R Agonist Asc30 Demonstrated an Observed Half-Life of 75 Days in Participants With Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2566374696","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566374696?lang=en_us&edition=fundamental","pubTime":"2025-09-09 18:30","pubTimestamp":1757413806,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nTUA6LLHLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"1184695411","title":"ASCLETIS-B (01672): Small Molecule GLP-1R Agonist ASC30's Ultra-Long-Acting Subcutaneous Depot Formulation for Weight Maintenance Demonstrates 75-Day Apparent Half-Life in Obese Subjects","url":"https://stock-news.laohu8.com/highlight/detail?id=1184695411","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184695411?lang=en_us&edition=fundamental","pubTime":"2025-09-09 18:22","pubTimestamp":1757413368,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced that its small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist ASC30's ultra-long-acting subcutaneous depot formulation for weight maintenance demonstrated a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01672","BK4590","BK1161","GLP","BK1574","BK1191","BK4144","01477"],"gpt_icon":0},{"id":"2566695088","title":"Ascletis Pharma Inc. Announces Phase IIa Study of ASC30 for Obesity Treatment with Promising Half-Life Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2566695088","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566695088?lang=en_us&edition=fundamental","pubTime":"2025-09-09 18:21","pubTimestamp":1757413314,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has announced the development of ASC30, an investigational GLP-1R biased small molecule agonist designed for both oral and subcutaneous administration. In a U.S. Phase Ib clinical study, ASC30's ultra-long-acting subcutaneous depot formulation demonstrated an observed half-life of 75 days in participants with obesity, supporting once-quarterly administration as a maintenance therapy for chronic weight management. Additionally, the ASC30 treatment formulation has shown an observed half-life of 46 days, indicating potential for once-monthly administration. Topline data from the Phase IIa study for ASC30 treatment formulation are expected in the first quarter of 2026. The company holds patent protection for ASC30, a new chemical entity, until 2044.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL9ZnHs1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","BK1574","01672"],"gpt_icon":0},{"id":"1179618919","title":"Yiteng Pharmaceuticals, Shanghai Pudong Development Bank Hong Kong Branch, Suzhou Branch, and SPDB International Sign Strategic Cooperation Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=1179618919","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179618919?lang=en_us&edition=fundamental","pubTime":"2025-09-09 18:21","pubTimestamp":1757413288,"startTime":"0","endTime":"0","summary":"On the afternoon of September 3, 2025, Yiteng Pharmaceuticals, Shanghai Pudong Development Bank Hong Kong Branch, Shanghai Pudong Development Bank Suzhou Branch, and SPDB International signed a...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0469268626.HKD","BK0028","BK0086","09939","BK0187","159938","SGXZ81163826.USD","LU1808992512.USD","600000","BK0015","BK0201","BK1515","BK1161","LU1979443071.USD","BK0188","SGXZ49509284.SGD","BK0183","BK0012","LU1934453819.USD","BK0278"],"gpt_icon":0},{"id":"2566466712","title":"BYD Electronic (International)  Stock Slides 2.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2566466712","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566466712?lang=en_us&edition=fundamental","pubTime":"2025-09-09 16:33","pubTimestamp":1757406780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of BYD Electronic  Co. Ltd. slipped 2.0% to 42.12 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.2% to 25938.13.The stock's fall snapped a three-day winning streak.BYD Electronic  Co. Ltd. closed 32% below its 52-week high of HK$61.55, which the company achieved Feb. 13.The stock underperformed when compared to some of its competitors, as Times Universal Group Holdings Ltd. remained unchanged.Trading volume totaled 21.6 million shares, compared to the 50-day average of 29.8 million shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","00285","LU0348766576.USD","BK1540","BK1580","BK1582","LU0348767384.USD","BK1149","BK1504","BK1589","LU0274383008.USD","BK1607"],"gpt_icon":1},{"id":"1126765801","title":"ALI HEALTH Surges Over 6% in Morning Trading as Analysts Expect Company to Benefit from Strong Demand for Innovative Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1126765801","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126765801?lang=en_us&edition=fundamental","pubTime":"2025-09-09 12:20","pubTimestamp":1757391650,"startTime":"0","endTime":"0","summary":"ALI HEALTH (00241) surged 6.63% in morning trading, currently trading at HK$6.92 with a turnover of HK$1.193 billion. HSBC Global Research noted that health products are expected to continue being...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1142","BK1615","BK1589","BK1502","BK1247","BK1501","BK1189","BK1584","BK1591","BK1515","BK1571","BK1610","00241","BK1617"],"gpt_icon":1},{"id":"1146069463","title":"CISI FIN Maintains \"Buy\" Rating on BYD ELECTRONIC (00285), Profitability Improves in 2025H1","url":"https://stock-news.laohu8.com/highlight/detail?id=1146069463","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146069463?lang=en_us&edition=fundamental","pubTime":"2025-09-09 11:42","pubTimestamp":1757389351,"startTime":"0","endTime":"0","summary":"CISI FIN issued a research report maintaining a \"buy\" rating on BYD ELECTRONIC (00285), projecting the company's revenue for 2025-2027 at RMB 189.5/205.8/223.3 billion respectively, with net profit...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1582","LU0348766576.USD","LU0348767384.USD","BK1504","BK1149","BK1515","06058","BK1580","00285","LU0274383008.USD","BK1540","BK1589","BK1607","BK1147","BK1564"],"gpt_icon":1},{"id":"2566652502","title":"Sihuan Pharmaceutical Receives Chinese Regulatory Nod for Human Studies of Diabetes Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2566652502","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566652502?lang=en_us&edition=fundamental","pubTime":"2025-09-09 10:31","pubTimestamp":1757385061,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical  said Chinese regulators approved its experimental P052 injection for human studies, according to a Hong Kong bourse filing Tuesday.The company is developing P052 as a treatment for type 2 diabetes and obesity.The drug has a mechanism similar to Novo Nordisk's semaglutide.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1593","00460","BK1600","BK1191"],"gpt_icon":0},{"id":"1111009005","title":"Hong Kong Stocks Movement | Most Internet Healthcare Stocks Rise as National Medical Products Administration Regulates Online Prescription Drug Retail, Institutions Recommend Focusing on Industry Recovery Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=1111009005","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111009005?lang=en_us&edition=fundamental","pubTime":"2025-09-09 10:22","pubTimestamp":1757384544,"startTime":"0","endTime":"0","summary":"Most internet healthcare stocks posted gains during trading. As of press time, DINGDANG HEALTH (09886) surged 8.54% to HK$0.89; ALI HEALTH (00241) climbed 6.16% to HK$6.89; FANGZHOU JIANKE (06086)...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1502","BK1617","BK1501","BK1583","09886","00241","BK1584","BK1589","BK1515","06618","86618","BK1610","BK1571","LU0051755006.USD","BK1189","BK1615","BK1247","BK1591","06086","LU0456827905.SGD","BK1142"],"gpt_icon":1},{"id":"1161833173","title":"Hong Kong Stocks Movement | JUNSHI BIO (01877) Surges Over 9% as JS005 Achieves Positive Results in Phase III Clinical Trial for Moderate to Severe Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=1161833173","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161833173?lang=en_us&edition=fundamental","pubTime":"2025-09-09 10:02","pubTimestamp":1757383338,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) surged over 9%, and as of press time, the stock was up 8.36% to HK$38.36 with a turnover of HK$173 million. On the news front, JUNSHI BIO announced that its recombinant humanized...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","BK1583","BK0239","BK1161","688180","BK1515"],"gpt_icon":0},{"id":"2566965651","title":"BRIEF-Sihuan Pharmaceutical Says P052 Injection Approved For Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2566965651","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566965651?lang=en_us&edition=fundamental","pubTime":"2025-09-09 09:33","pubTimestamp":1757381597,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharmaceutical Says P052 Injection Approved For IndSept 9 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:P052 INJECTION INDEPENDENTLY DEVELOPED BY HUISHENG BIOPHARMACEUTICAL APPROVED FOR INDFurther company coverage: 0460.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nFWN3UV1CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1600","00460","BK1191","BK1593"],"gpt_icon":0},{"id":"1153469279","title":"Morgan Stanley Initiates Buy Rating on FOSUN PHARMA (02196) with A-Share Target Price of 42 RMB and H-Share Target Price of 33 HKD","url":"https://stock-news.laohu8.com/highlight/detail?id=1153469279","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153469279?lang=en_us&edition=fundamental","pubTime":"2025-09-09 08:34","pubTimestamp":1757378072,"startTime":"0","endTime":"0","summary":"According to recent reports, international investment bank Morgan Stanley has released a latest research report stating that FOSUN PHARMA (600196.SH, 02196) is demonstrating improving profitability...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0196","BK0012","BK0183","02196","BK0188","BK1191","600196","BK0175","BK0239","BK1515","159982","BK0187","BK0060","BK1593","399300","BK0028"],"gpt_icon":0},{"id":"1131898226","title":"SIHUAN PHARM (00460): Subsidiary Huisheng Bio Receives IND Approval for Self-Developed GLP-1R/GCGR Dual-Target Innovative Drug P052 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1131898226","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131898226?lang=en_us&edition=fundamental","pubTime":"2025-09-09 08:16","pubTimestamp":1757376982,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) announced that its non-wholly owned subsidiary, Huisheng Biopharmaceutical Co., Ltd. (Huisheng Bio), has received tacit approval from the Center for Drug Evaluation (CDE) of the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1191","06978","BK1574","BK1515","BK1593","BK4590","BK1600","GLP","159992","BK4144","00460"],"gpt_icon":0},{"id":"2566653655","title":"Sihuan Pharmaceutical - P052 Injection Independently Developed by Huisheng Biopharmaceutical Approved for Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2566653655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566653655?lang=en_us&edition=fundamental","pubTime":"2025-09-09 08:02","pubTimestamp":1757376174,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nFWN3UV1CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","BK1191","BK1515","00460","BK1600"],"gpt_icon":0},{"id":"1156364553","title":"KINTOR PHARMA-B (09939): KT-939 Human Long-term Safety Trial Completes Full Subject Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=1156364553","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156364553?lang=en_us&edition=fundamental","pubTime":"2025-09-09 06:20","pubTimestamp":1757370026,"startTime":"0","endTime":"0","summary":"KINTOR PHARMA-B (09939) announced that its independently developed novel high-efficiency tyrosinase inhibitor KT-939, which inhibits melanin production, has recently completed enrollment of all 130...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0541501648.USD","LU0541502299.USD","BK1515","KT","09939","BK1161","BK4115"],"gpt_icon":0},{"id":"2566630254","title":"Kintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939","url":"https://stock-news.laohu8.com/highlight/detail?id=2566630254","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566630254?lang=en_us&edition=fundamental","pubTime":"2025-09-09 06:12","pubTimestamp":1757369567,"startTime":"0","endTime":"0","summary":"Kintor Pharmaceutical Ltd. Announces Completion of Enrollment for Long-Term Human Safety Trial of Novel Tyrosinase Inhibitor KT-939. Kintor Pharmaceutical Ltd. has announced the completion of enrollment for a long-term human safety trial of their novel tyrosinase inhibitor, KT-939. The study involves 130 subjects and aims to evaluate the safety of topical application of 0.2% KT-939 over 48 consecutive weeks. This trial has received approval from the Ethics Committee of Shanghai Skin Disease Hospital and is led by Professor Tan Yimei. The primary focus is on any adverse skin reactions related to the use of KT-939, which is designed to inhibit melanin production and has demonstrated antioxidant and anti-inflammatory effects. Previous trials have shown favorable efficacy and safety profiles. The results of the current long-term safety trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL4TRbDf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","09939","BK1574","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":185,"code":"91000000","status":"200"}]}}